ClinicalTrials.gg

Anus Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 298 studies for Anus Neoplasms across more than 10 countries. 75 are recruiting or about to start. 155 of them are mainly about Anus Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Anal Canal Carcinoma too: 314 studies, 79 open.

Status

Completed
132
Recruiting
57
Active, not recruiting
31
Terminated
26
Status unknown
26
Not yet recruiting
15

Phase

Phase 2
83
Phase 1
69
Phase 3
25
Phase 4
2

Where

United States
162
France
26
China
17
Canada
15
United Kingdom
14
Denmark
12

Who develops what

Add Anus Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
FluorouracilRecent, limited
Evidence
  • NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
  • NCT03221400 · Tarveda Therapeutics · Phase 2 · background · “fluorouracil” · registered Jul 2017
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed11 study
LeucovorinRecent, limited
Evidence
  • NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “mFOLFIRINOX Treatment Regimen” · registered Nov 2025
  • NCT03221400 · Tarveda Therapeutics · Phase 2 · background · “Folinic acid” · registered Jul 2017
Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed11 study
atezolizumabRecent, limited
Evidence
  • NCT07280377 · Oncolytics Biotech · Phase 2 · live · background · “Atezolizumab” · registered Nov 2025
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)11 study

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Jul 2027 est.pelareorep · Oncolytics Biotech · Phase 2 main aimstudied with atezolizumabstudied with GNP Regimenstudied with trifluridine tipiracil drug combinationNCT07280377 A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab — primary endpoint: Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5 · 122 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Anus Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 7 open · Antimetabolites 1 open · Alkylating agents 1 open · Antimitotic agents 1 open · Tyrosine kinase inhibitors (TKIs) 1 open

Coming up

30studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 57 Anus Neoplasms studies recruiting now, 46 (81%) set no upper age limit and 7 (12%) stop at 75 or younger. 3 (5%) take children under 18. 7 (12%) are for women only and 2 (4%) for men only; 6 (11%) take healthy volunteers.

Recruiting studies that take each age, of 57
AgeWomenMen
102 (4%)1 (2%)
1850 (88%)47 (82%)
3051 (89%)47 (82%)
4054 (95%)49 (86%)
5055 (96%)49 (86%)
6555 (96%)49 (86%)
7554 (95%)48 (84%)
8548 (84%)42 (74%)

Across all 298 studies, recruiting or not: 14% stop at 75 or younger and 7% at 65; 8% take children; 8% are for women only and 9% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Anus Neoplasms studies take

Of 40 phase 2 interventional studies under Anus Neoplasms, half reached primary completion within 62 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 146 mo27–57 · 20 studies——
Phase 262 mo42–105 · 40 studies——
Interventional, no phase52 mo17–… · 39 studies——
Observational44 mo32–137 · 36 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 298. Browse all 298 → or search them.